I want to break down what I and others mean when we say that pharmaceutical companies did not properly prepare for #COVID19 despite previous warnings we could have a pandemic.
So, what was done with the knowledge of that massive public health threat?

Not enough. Global R&D investment for neglected diseases is around $4b. Of that investment, the private sector contributed just 17% - not even 1/10th of the revenue of the top 20 pharma companies in 2019.
There are lots of (troubling) reasons for the disconnect between need and action.

For one, outbreaks rarely last long enough to ensure the private sector gets their ROI. Also, poor people in low-income countries often affected by these diseases don't = a profitable market.
But now that #COVID19 is affecting the economies of the richest countries, we are seeing $ billions of dollars being invested on new vaccines and treatments. The same happened with the recent Ebola outbreak.
In the case of #COVID19 (and many other public health crises) the current market-based model incentivises companies to find new ways (like patent manipulation) to keep existing drugs profitable instead of conducting R&D into new drugs/vaccines for public health.
Ultimately, our system for new drug/vaccine development did not prepare us for when we needed it most. The time to reimagine this model is now.
You can follow @realtahiramin.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: